These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 18983609

  • 1. Activation of the NF-kappaB signalling pathway in diffuse large B-cell lymphoma: clinical implications.
    Espinosa I, Briones J, Bordes R, Brunet S, Martino R, Sureda A, Sierra J, Prat J.
    Histopathology; 2008 Oct; 53(4):441-9. PubMed ID: 18983609
    [Abstract] [Full Text] [Related]

  • 2. Bcl-10 protein highly correlates with the expression of phosphorylated p65 NF-kappaB in peripheral T-cell lymphomas and is associated with clinical outcome.
    Briones J, Moga E, Espinosa I, Vergara C, Alvarez E, Villa J, Bordes R, Delgado J, Prat J, Sierra J.
    Histopathology; 2009 Mar; 54(4):478-85. PubMed ID: 19309400
    [Abstract] [Full Text] [Related]

  • 3. The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) induces apoptosis of human diffuse large B-cell lymphoma cells through a peroxisome proliferator-activated receptor gamma-independent pathway.
    Ray DM, Morse KM, Hilchey SP, Garcia TM, Felgar RE, Maggirwar SB, Phipps RP, Bernstein SH.
    Exp Hematol; 2006 Sep; 34(9):1202-11. PubMed ID: 16939813
    [Abstract] [Full Text] [Related]

  • 4. NF-kappaB activation through the alternative pathway correlates with chemoresistance and poor survival in extranodal NK/T-cell lymphoma, nasal type.
    Liu X, Wang B, Ma X, Guo Y.
    Jpn J Clin Oncol; 2009 Jul; 39(7):418-24. PubMed ID: 19395464
    [Abstract] [Full Text] [Related]

  • 5. Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients.
    Montagut C, Tusquets I, Ferrer B, Corominas JM, Bellosillo B, Campas C, Suarez M, Fabregat X, Campo E, Gascon P, Serrano S, Fernandez PL, Rovira A, Albanell J.
    Endocr Relat Cancer; 2006 Jun; 13(2):607-16. PubMed ID: 16728586
    [Abstract] [Full Text] [Related]

  • 6. Clinicopathological implications of nuclear factor κB signal pathway activation in diffuse large B-cell lymphoma.
    Zhao Q, Fu W, Jiang H, Du J, Zhang C, Xi H, Zhou F, Li R, Hou J.
    Hum Pathol; 2015 Apr; 46(4):524-31. PubMed ID: 25636172
    [Abstract] [Full Text] [Related]

  • 7. The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL).
    Bavi P, Uddin S, Bu R, Ahmed M, Abubaker J, Balde V, Qadri Z, Ajarim D, Al-Dayel F, Hussain AR, Al-Kuraya KS.
    J Pathol; 2011 Jul; 224(3):355-66. PubMed ID: 21506127
    [Abstract] [Full Text] [Related]

  • 8. Activation of NF-kappaB by Toxoplasma gondii correlates with increased expression of antiapoptotic genes and localization of phosphorylated IkappaB to the parasitophorous vacuole membrane.
    Molestina RE, Payne TM, Coppens I, Sinai AP.
    J Cell Sci; 2003 Nov 01; 116(Pt 21):4359-71. PubMed ID: 12966164
    [Abstract] [Full Text] [Related]

  • 9. Calbindin-D28K expression induced by glial cell line-derived neurotrophic factor in substantia nigra neurons dependent on PI3K/Akt/NF-kappaB signaling pathway.
    Wang HJ, Cao JP, Yu JK, Zhang LC, Jiang ZJ, Gao DS.
    Eur J Pharmacol; 2008 Oct 24; 595(1-3):7-12. PubMed ID: 18703048
    [Abstract] [Full Text] [Related]

  • 10. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
    Buchholz TA, Garg AK, Chakravarti N, Aggarwal BB, Esteva FJ, Kuerer HM, Singletary SE, Hortobagyi GN, Pusztai L, Cristofanilli M, Sahin AA.
    Clin Cancer Res; 2005 Dec 01; 11(23):8398-402. PubMed ID: 16322301
    [Abstract] [Full Text] [Related]

  • 11. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
    Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, Banham AH, Enblad G, Leppä S.
    Eur J Haematol; 2009 May 01; 82(5):364-72. PubMed ID: 19141121
    [Abstract] [Full Text] [Related]

  • 12. Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas.
    van Galen JC, Muris JJ, Giroth CP, Vos W, Ossenkoppele GJ, Meijer CJ, Oudejans JJ.
    Histopathology; 2008 Apr 01; 52(5):578-84. PubMed ID: 18312353
    [Abstract] [Full Text] [Related]

  • 13. Immunohistochemical analysis of NF-kappaB signaling proteins IKKepsilon, p50/p105, p52/p100 and RelA in prostate cancers.
    Seo SI, Song SY, Kang MR, Kim MS, Oh JE, Kim YR, Lee JY, Yoo NJ, Lee SH.
    APMIS; 2009 Aug 01; 117(8):623-8. PubMed ID: 19664134
    [Abstract] [Full Text] [Related]

  • 14. Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer.
    Guo RX, Qiao YH, Zhou Y, Li LX, Shi HR, Chen KS.
    Pathol Int; 2008 Dec 01; 58(12):749-56. PubMed ID: 19067848
    [Abstract] [Full Text] [Related]

  • 15. Protein kinase Cdelta activates RelA/p65 and nuclear factor-kappaB signaling in response to tumor necrosis factor-alpha.
    Lu ZG, Liu H, Yamaguchi T, Miki Y, Yoshida K.
    Cancer Res; 2009 Jul 15; 69(14):5927-35. PubMed ID: 19549902
    [Abstract] [Full Text] [Related]

  • 16. RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma.
    Zhang M, Xu-Monette ZY, Li L, Manyam GC, Visco C, Tzankov A, Wang J, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Han van Krieken J, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Piris MA, Medeiros LJ, Pham LV, Young KH.
    Aging (Albany NY); 2016 Dec 08; 8(12):3321-3340. PubMed ID: 27941215
    [Abstract] [Full Text] [Related]

  • 17. Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma.
    Feng W, Brown RE, Trung CD, Li W, Wang L, Khoury T, Alrawi S, Yao J, Xia K, Tan D.
    Ann Clin Lab Sci; 2008 Dec 08; 38(3):195-209. PubMed ID: 18715846
    [Abstract] [Full Text] [Related]

  • 18. Large B-cell lymphoma with Hodgkin's features.
    García JF, Mollejo M, Fraga M, Forteza J, Muniesa JA, Pérez-Guillermo M, Pérez-Seoane C, Rivera T, Ortega P, Piris MA.
    Histopathology; 2005 Jul 08; 47(1):101-10. PubMed ID: 15982329
    [Abstract] [Full Text] [Related]

  • 19. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma.
    Obermann EC, Csato M, Dirnhofer S, Tzankov A.
    J Clin Pathol; 2009 Oct 08; 62(10):903-7. PubMed ID: 19783718
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions.
    Ok CY, Xu-Monette ZY, Li L, Manyam GC, Montes-Moreno S, Tzankov A, Visco C, Dybkær K, Routbort MJ, Zhang L, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Rao H, Møller MB, Winter JN, Piris MA, Wang SA, Medeiros LJ, Young KH.
    Mod Pathol; 2015 Sep 08; 28(9):1202-13. PubMed ID: 26111978
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.